Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Cannot have received: radioisotope therapy (Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223)

Exception: allowed if >6 months prior

Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation <6 months prior to date of first administration of investigational drug

Cannot have received: PSMA-targeted radioligand therapy

Previous PSMA-targeted radioligand therapy

Cannot have received: radiotherapy

Exception: allowed if >4 weeks prior

Previous radiotherapy for prostate cancer within 4 weeks prior to date of first administration of investigational drug

Cannot have received: systemic anti-cancer therapy (chemotherapy, immunotherapy, poly adenosine diphosphate-ribosyl polymerase inhibitors (PARPi), biological therapy)

Exception: allowed if >4 weeks prior

Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy, poly adenosine diphosphate-ribosyl polymerase inhibitors (PARPi) or biological therapy within 4 weeks prior to date of first administration of investigational drug

Cannot have received: investigational therapy

Exception: allowed if >4 weeks prior

Must not take part in other investigational therapies within 4 weeks prior to date of first administration of investigational drug